Advanced search
Publication Cover
Expert Review of Proteomics Volume 8, 2011 - Issue 3
Submit an article Journal homepage
524
Views
6
CrossRef citations to date
0
Altmetric
Editorial

Neuroproteomics and Parkinson’s disease: don’t forget human samples

Virginie Licker Neuroproteomics Group, University Medical Center, Faculty of Medicine, University of Geneva, Geneva, Switzerland
&
Pierre R Burkhard Neuroproteomics Group, University Medical Center, Faculty of Medicine, University of Geneva and Department of Neurology, Geneva University Hospitals, Geneva, Switzerland. [email protected]
Pages 291-294 | Published online: 09 Jan 2014

References

  • Thomas B, Beal MF. Parkinson’s disease. Hum. Mol. Genet.16(R2), 183–194 (2007).
  • Poewe W. Non-motor symptoms in Parkinson’s disease. Eur. J. Neurol.15(Suppl. 1), 14–20 (2008).
  • Marsden CD. Parkinson’s disease. Lancet335(8695), 948–952 (1990).
  • Brundin P, Li J-Y, Holton JL, Lindvall O, Revesz T. Research in motion: the enigma of Parkinson’s disease pathology spread. Nature9(10), 741–745 (2008).
  • Sulzer D. Multiple hit hypotheses for dopamine neuron loss in Parkinson’s disease. Trends Neurosci.30(5), 244–250 (2007).
  • Braak H, Del Tredici K, Rub U et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol. Aging24(2), 197–211 (2003).
  • Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K. Stages in the development of Parkinson’s disease-related pathology. Cell Tissue Res.318, 121–134 (2004).
  • Singleton A, Gwinn-Hardy K. Parkinson’s disease and dementia with Lewy bodies: a difference in dose? Lancet364(9440), 1105–1107 (2004).
  • Polymeropoulos M, Lavedan C, Leroy E et al. Mutation in the α-synuclein gene identified in families with Parkinson’s disease. Science276, 2045–2047 (1997).
  • Schiesling C, Kieper N, Seidel K, Kruger R. Review: familial Parkinson’s disease – genetics, clinical phenotype and neuropathology in relation to the common sporadic form of the disease. Neuropathol. Appl. Neurobiol.34(3), 255–271 (2008).
  • Clark LN, Wang Y, Karlins E et al. Frequency of LRRK2 mutations in early- and late-onset Parkinson disease. Neurology67(10), 1786–1791 (2006).
  • Ozelius LJ, Senthil G, Saunders-Pullman R et al. LRRK2 G2019S as a cause of Parkinson’s disease in Ashkenazi Jews. N. Engl. J. Med.354(4), 424–425 (2006).
  • Wirdefeldt K, Gatz M, Schalling M, Pedersen NL. No evidence for heritability of Parkinson disease in Swedish twins. Neurology63(2), 305–311 (2004).
  • Lees AJ, Hardy J, Revesz T. Parkinson’s disease. Lancet373(9680), 2055–2066 (2009).
  • Tanner CM. Advances in environmental epidemiology. Mov. Disord.25(S1), 58–62 (2010).
  • Consortium IPDG. Imputation of sequence variants for identification of genetic risks for Parkinson’s disease: a meta-analysis of genome-wide association studies. Lancet377(9766), 641–649 (2011).
  • Licker V, Kovari E, Hochstrasser DF, Burkhard PR. Proteomics in human Parkinson’s disease research. J. Proteomics73(1), 10–29 (2009).
  • Beal MF. Parkinson’s disease: a model dilemma. Nature466(7310), 8–10 (2010).
  • Potashkin JA, Blume SR, Runkle NK. Limitations of animal models of Parkinson’s disease. Parkinsons Dis.2011, 658083 (2010).
  • Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain125(Pt 4), 861–870 (2002).
  • Tokuda T, Salem SA, Allsop D et al. Decreased α-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson’s disease. Biochem. Biophys. Res. Commun.349(1), 162–166 (2006).
  • Mollenhauer B, Cullen V, Kahn I et al. Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp. Neurol.213(2), 315–325 (2008).
  • Hong Z, Shi M, Chung KA et al. DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease. Brain133(Pt 3), 713–726 (2010).
  • Zhang J, Sokal I, Peskind ER et al. CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am. J. Clin. Pathol.129(4), 526–529 (2008).
  • Eller M, Williams DR. Biological fluid biomarkers in neurodegenerative parkinsonism. Nat. Rev. Neurol.5(10), 561–570 (2009).
  • Crecelius A, Gotz A, Arzberger T et al. Assessing quantitative post-mortem changes in the gray matter of the human frontal cortex proteome by 2-D DIGE. Proteomics8(6), 1276–1291 (2008).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.